Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 10 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 10 W O ELECTROLYTES.
AMINOSYN II 8.5% W/ELECTROLYTES vs TRAVASOL 10% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Travasol 10% w/o electrolytes is a parenteral nutrition solution containing essential and non-essential amino acids. The amino acids provide substrates for protein synthesis, thereby supporting tissue repair, growth, and maintenance. The solution also provides a source of nitrogen and caloric replacement.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
10% amino acid solution administered intravenously via central line at 0.5-1.0 g amino acids/kg/day, not to exceed 2.5 g/kg/day; typical infusion rate 50-125 mL/hr.
None Documented
None Documented
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
The terminal elimination half-life of infused amino acids is approximately 1-2 hours, reflecting rapid metabolism and clearance. Clinical context: Steady state is achieved within 1-2 hours of continuous infusion.
Renal >90% (as amino acids and metabolites); fecal <5%
Amino acids are primarily metabolized; nitrogen is excreted renally as urea (∼85-90%), with small amounts in feces (∼5%) and minimal biliary elimination. Electrolytes are excreted renally, with excretion proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution